ArticleCardiology and therapy2025
Arterial Hypertension and Associated Risk Factors in Kazakhstan: An Analysis of Blood Pressure Screening Results from May Measurement Month 2021-2023.
Article in Cardiology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessment of Health Status in Populations Living in the Semipalatinsk Nuclear Test Site Region: Results of Screening.Healthcare (Basel, Switzerland) · 2026Article
- Gender and Age Differences in Hypertension Screening and Cardiovascular Risk Factors in Rural Kazakhstan.Vascular health and risk management · 2026Article
- Adherence to Antihypertensive Therapy: A Cross-Sectional Study Among Patients in the Republic of Kazakhstan.International journal of environmental research and public health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMay Measurement Month (MMM) is a global campaign with the aim to improve awareness of arterial hypertension (AH). Kazakhstan participated in the campaign in 2021, 2022 and 2023.
methodsDuring the cross-sectional 2021-2023 MMM surveys, volunteer adults (≥ 18 years) from cities in Kazakhstan had their blood pressure (BP) measured three times in a seated position, and received a questionnaire on their demographics, lifestyle and medical history. In those not receiving antihypertensive treatment, AH was defined as a mean systolic and/or diastolic BP ≥ 140/90 mmHg.
resultsA total of 8231 individuals took part in the survey, with 1805 participants in 2021, 2410 participants in 2022 and 4016 participants in 2023. The prevalence of AH was estimated to be 37% in 2021 and 45% in 2022 and 2023. Of those identified as having AH, 51-70% were aware that they had the condition. Among those who were aware that they had AH, 68-91% were receiving antihypertensive therapy. However, 70-82% of treated participants were only receiving one to two drugs. BP was controlled to < 140/90 mmHg in 43-50% of treated participants and to < 130/80 mmHg in 15-16%.
conclusionThe 2021, 2022 and 2023 MMM campaigns showed that high proportion of AH, a low level of AH awareness and inadequate BP control in Kazakhstan. Programs are needed to increase awareness of the risks of high BP and to improve the diagnosis and effective treatment of AH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.